Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Many core facts (indications, oral/non-absorbed, bile-acid binding, dose timing concept, GI obstruction/constipation risk, and 4-hour separation for interacting drugs) are supported by the provided label text. Several claims are either broader than the label evidence provided (e.g., 'not absorbed systemically' and 'most common side effects'), lack label support in the supplied sections (e.g., specific named GI side effects list; generic availability; statin/ezetimibe comparisons), or add management details not stated verbatim in the provided text.
Category Scores
Accurate Statements
Welchol is the brand name for colesevelam.
11 DESCRIPTION (WELCHOL (colesevelam hydrochloride))
Colesevelam is a cholesterol medication in the bile-acid sequestrant class.
1.1 Primary Hyperlipidemia; 11 DESCRIPTION (lipid-lowering agent; high-capacity bile acid-binding molecule)
Colesevelam works in the gut by binding bile acids.
11 DESCRIPTION (high-capacity bile acid-binding molecule; non-absorbed; oral polymeric agent)
Binding bile acids lowers LDL cholesterol levels.
1.1 Primary Hyperlipidemia (reduce elevated LDL-C); 11 DESCRIPTION (bile acid-binding molecule)
Colesevelam can improve cholesterol profiles.
1.1 Primary Hyperlipidemia (reduce LDL-C levels; adjunct to diet and exercise)
Colesevelam can be taken by mouth.
2.2 Recommended Dosage... (oral administration implied by dosage section); 11 DESCRIPTION (for oral administration)
Colesevelam is taken as an oral powder or tablet/other formulations depending on the product.
11 DESCRIPTION (WELCHOL tablets; WELCHOL for oral suspension packet contents)
Dosing and the exact product schedule depend on the indication (cholesterol vs. diabetes) and the strength/formulation prescribed.
2.2 Recommended Dosage... (adult primary hyperlipidemia and adult type 2 diabetes are 3.75 g daily; label also distinguishes hyperlipidemia vs diabetes and mentions formulations in 11 DESCRIPTION)
Worsening constipation with colesevelam may require dose adjustment or additional constipation management.
Not explicitly supported as dose adjustment; however label instructs discontinuation/seek medical attention if severe constipation occurs: 5.2 Gastrointestinal Obstruction (instruct patients to promptly discontinue... if severe abdominal pain or severe constipation occurs).
Colesevelam can reduce absorption of other medicines because it binds substances in the intestine.
5.4 Drug Interactions (reduces gastrointestinal absorption of some drugs)
Separating other oral drugs from colesevelam dosing can lower the risk of reduced effectiveness.
5.4 Drug Interactions (administer interacting drugs at least 4 hours prior to WELCHOL)
This separation is especially important for medications that must be taken at specific times for proper control.
5.4 Drug Interactions (especially those with a narrow therapeutic index; administer at least 4 hours prior). (Label provided does not use the phrase 'must be taken at specific times for proper control,' but the stated 'narrow therapeutic index' emphasis supports the general idea.)
In some patients with type 2 diabetes, colesevelam has been used to improve glycemic control when added to existing diabetes therapy.
1.2 Type 2 Diabetes Mellitus (adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus). (Supplied label excerpt does not explicitly say 'added to existing diabetes therapy' in those words.)
Colesevelam is not a replacement for standard diabetes treatment.
1.2 Type 2 Diabetes Mellitus (adjunct to diet and exercise). (Supplied excerpt does not explicitly state 'not a replacement for standard diabetes treatment,' but 'adjunct' wording supports that characterization.)
Colesevelam is not absorbed systemically.
11 DESCRIPTION (non-absorbed)
Colesevelam works by binding bile acids in the gut.
11 DESCRIPTION (high-capacity bile acid-binding molecule; non-absorbed; oral)
Colesevelam differs from statins because statins lower cholesterol synthesis in the liver.
No label support in provided sections for statin mechanism/comparison.
Colesevelam differs from ezetimibe because ezetimibe reduces cholesterol absorption.
No label support in provided sections for ezetimibe mechanism/comparison.
Colesevelam has generic equivalents depending on the specific formulation and market availability.
No label support provided in the supplied label text.
Unsupported Statements
Colesevelam can reduce absorption of other medicines because it binds substances in the intestine.
Label supports reduced gastrointestinal absorption (5.4) but the 'because it binds substances in the intestine' rationale is not explicitly stated in the provided text.
Some patients experience worsening constipation with colesevelam.
Label excerpt states constipating effects and not recommended in certain GI motility conditions; it does not explicitly say 'some patients experience worsening constipation.'
Worsening constipation with colesevelam may require dose adjustment or additional constipation management.
Label instructs discontinuation and seeking medical attention for severe constipation (5.2) but does not state dose adjustment or 'additional constipation management.'
Gastrointestinal side effects are the most common with colesevelam.
The provided label sections do not state that GI side effects are the 'most common.'
Reported gastrointestinal side effects of colesevelam include constipation, bloating, gas, and nausea.
The provided label excerpt does not list these specific GI adverse reactions.
In some patients with type 2 diabetes, colesevelam has been used to improve glycemic control when added to existing diabetes therapy.
Provided label excerpt states adjunct to diet and exercise (1.2) but does not describe add-on to existing diabetes therapy in the supplied text.
This separation is especially important for medications that must be taken at specific times for proper control.
Label emphasis is on drugs with narrow therapeutic index (5.4), not on 'specific times for proper control' wording.
Colesevelam differs from statins because statins lower cholesterol synthesis in the liver.
No statin comparison or mechanism is included in provided label text.
Colesevelam differs from ezetimibe because ezetimibe reduces cholesterol absorption.
No ezetimibe comparison or mechanism is included in provided label text.
Colesevelam’s cholesterol-lowering pattern and side-effect profile differ from statins.
No label support for comparative patterns or side-effect profile differences versus statins in provided text.
Colesevelam’s cholesterol-lowering pattern and side-effect profile differ from drugs like ezetimibe.
No label support for comparative patterns or side-effect profile differences versus ezetimibe in provided text.
Colesevelam has generic equivalents depending on the specific formulation and market availability.
No statement about generics/market availability is included in provided label text.
Contradictions
Low
AI Statement
Worsening constipation with colesevelam may require dose adjustment or additional constipation management.
Label Reference
5.2 Gastrointestinal Obstruction (instruct patients to promptly discontinue WELCHOL and seek medical attention if severe abdominal pain or severe constipation occurs).
Important Omissions
The label includes specific limitations of use for type 2 diabetes (e.g., should not be used for type 1 diabetes or diabetic ketoacidosis; not studied in certain Fredrickson dyslipidemias).
Importance:
Moderate
Monitoring: label states to monitor lipid levels within 4 to 6 weeks after initiation of WELCHOL (primary hyperlipidemia/primary indication dosing section).
Importance:
Moderate
Bowel obstruction risk: label specifically contraindicated in patients with a history of bowel obstruction and not recommended in patients at risk (gastroparesis, other motility disorders, major GI surgery).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-relevant details are missing or broadened beyond provided label text: GI adverse reaction frequency and specific GI symptoms are not supported by the excerpt; management language about dose adjustment is not stated (label instead directs discontinuation and medical attention for severe constipation/abdominal pain). Omission of explicit limitations of use and specific GI obstruction risk caveats could affect safe use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided label text (specific GI symptom list; 'most common' frequency; statin/ezetimibe comparisons; generic availability; add-on therapy phrasing), and constipation management wording does not match the label (label emphasizes discontinuation and medical attention for severe constipation).
Suggested Improvement
Restrict statements to label-supported content: use 'constipating effects' and 'severe constipation—discontinue and seek medical attention' (5.2) rather than implying dose adjustment; omit unlabelled comparisons (statins/ezetimibe) and generic availability; avoid claiming frequency ('most common') or specific GI symptom list unless included in the provided prescribing information.